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Lactobacillus gasseri APC 678
Reduces Shedding of the Pathogen
Clostridium difficile in a Murine
Model
Lisa Quigley1,2†, Mairéad Coakley1,2†, Debebe Alemayehu1,2, Mary C. Rea1,2,
Patrick G. Casey2,3, Órla O’Sullivan1,2, Eileen Murphy4, Barry Kiely4, Paul D. Cotter1,2,
Colin Hill2,3 and R. Paul Ross1,2,3*
1 Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland, 2 APC Microbiome Ireland, University College Cork,
Cork, Ireland, 3 School of Microbiology, University College Cork, Cork, Ireland, 4 Alimentary Health Ltd., Cork, Ireland
Clostridium difficile is a common cause of health-care acquired diarrhea, resulting in a
spectrum of disease from mild diarrhea to life-threatening illness. Sixty Lactobacillus
strains were screened for anti-C. difficile activity using a co-culture method. Based
on their ability to inhibit C. difficile, L. gasseri APC 678 and L. rhamnosus DPC 6111
were selected for study in a murine model of C. difficile infection. L. gasseri ATCC
33323, was included as a control. It was established that, relative to control mice not
fed Lactobacillus, feeding with L. gasseri APC 678 resulted in a significant reduction
by day 7 (8-fold, p = 0.017) of viable C. difficile VPI 10463 in the feces of mice. In
contrast, neither L. rhamnosus DPC 6111 nor L. gasseri ATCC 33323 significantly
reduced fecal C. difficile shedding. Sequencing of the cecal microbiota showed that
in mice fed L. gasseri APC 678 there was a significant increase in bacterial diversity
across a number of indices when compared to the control or other Lactobacillus-fed
groups. There was no significant change in the relative abundance of Firmicutes or
Bacteroidetes in the group fed L. gasseri APC 678 relative to the control, while the
groups fed L. rhamnosus DPC 6111 or L. gasseri ATCC 33323 showed a significant
decrease in the relative abundance of Firmicutes (p = 0.002 and p = 0.019, respectively)
and a significant increase in Bacteroidetes (p = 0.002 and p = 0.023, respectively).
These results highlight the potential of L. gasseri APC 678 as a live therapeutic agent to
target C. difficile infection.
Keywords: Lactobacillus gasseri, Clostridium difficile, C. difficile infection (CDI), murine model, live
therapeutic agent
Abbreviations: BHI, brain heart infusion; CCEY, cefoxitin cycloserine and egg yolk agar; CDI, C. difficile infection;
CLA, conjugated linoleic acid; EFSA, European Food Safety Authority; ENA, European Nucleotide Archive; ESCMID,
European Society of Clinical Microbiology and Infectious Diseases; FMT, fecal microbiota transplantation; GABA, gamma-
aminobutyric acid; GIT, gastrointestinal tract; HPRA, Health Products Regulatory Authority of Ireland; MGM, minimal
growth medium; MRD, maximum recovery diluent; MRS, de Man Rogosa Sharpe; OD, optical density; OTU, operational
taxonomical unit; PBS, phosphate buffered saline; PCoA, principal coordinates analysis; QPS, qualified presumption of safety;
RCM, reinforced clostridial medium; RSM, reconstituted skim milk; SCFA, short chain fatty acid; SFI, Science Foundation
Ireland.
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INTRODUCTION
Clostridium difficile is a Gram positive, cytotoxin-producing
anaerobic intestinal pathogen with an asymptomatic carriage
rate of up to 30% in people in long-term care facilities
(Ziakas et al., 2015). The bacterium has recently been
reclassified as Clostridioides difficile (Lawson et al., 2016). When
the human intestinal microbiota is altered following broad
spectrum antibiotic therapy, C. difficile may flourish and cause
illness, varying from mild diarrhea (usually self-limiting) to
pseudomembranous colitis, fulminant colitis, toxic mega-colon
and even death (Kachrimanidou and Malisiovas, 2011). The
incidences of CDI have rapidly increased since the 1990s, and the
mortality rate has also grown markedly (Wiegand et al., 2012).
Recent studies indicate that the economic burden of C. difficile
is mounting as a result of increased incidences of infection
in hospitalized patients. Estimates show that the economic
health-care costs of CDI are over $4.8 billion per annum in
the United States and over €3 billion per annum in Europe
(DePestel and Aronoff, 2013).
The ESCMID guidelines for treatment of CDI include
antibiotics, toxin-binding resins and polymers, immunotherapy,
probiotics and fecal or bacterial intestinal transplantation
(Debast et al., 2014). Antibiotic treatment is typically advised,
including the use of metronidazole, vancomycin and fidaxomicin
(Debast et al., 2014). However, as standard therapies for CDI
frequently have limited efficacy, the search for alternative
therapies including live therapeutics and bacteriocins such as
thuricin CD that may reduce incidences and recurring infections
are gaining credence (Rea et al., 2013; Evans and Johnson,
2015; Goldstein et al., 2015). One of the strategies used to
modulate the gut microbiota is the dietary administration of
live microorganisms (Hill et al., 2014). A meta-analysis of the
literature, from 1985 to 2013, found that the use of probiotics
significantly prevented CDI and antibiotic-associated diarrhea
in children, but that the effect of the probiotics was strain
dependent (McFarland and Goh, 2013). The mode of action of
live therapeutics is multi-faceted and includes an improvement
in epithelial barrier function, immune-modulation, secretion
of antimicrobial substances (e.g., bacteriocins and hydrogen
peroxide) and bioactive metabolites (e.g., CLA), inhibition of
the expression of virulence factors, playing a role in competitive
exclusion possibly through colonization resistance or through
the production of neurotransmitters such as GABA, which may
impact on brain function (Dobson et al., 2012; O’Shea et al., 2012;
Sultana et al., 2013; Nebot-Vivinus et al., 2014; Dinan et al., 2015;
Fernandez et al., 2015). However, the effect of pure cultures of
bacterial strains administered as live therapeutics has been shown
in many instances to be strain rather than species dependent
indicating that careful strain selection is required (Wall et al.,
2012). Lactobacilli are commonly used as probiotics, having
health impacts as outlined above, with a range of lactobacilli
(including L. gasseri and L. rhamnosus) on the EFSA list of
microorganisms suitable for use in food and feed production
(Ricci et al., 2017).
More recently FMT has been used with some success for the
treatment of refractory CDI and interest in this area has risen as
evidenced by the large increase in publications relating to FMT
over the last number of years (Bojanova and Bordenstein, 2016).
To date the mechanism of action of FMT to break the cycle
of recurrent CDI has remained poorly understood. However,
intra-colonic bile acid has been suggested to play a role in both
spore germination and inhibition of vegetative cells of C. difficile
(Weingarden et al., 2016). Clostridium scindens, a member of
the intestinal microbiota capable of dehydroxylating bile acid,
was shown to be associated with resistance to C. difficile and
enhanced resistance to infection in a murine model of CDI
(Buffie et al., 2015).
Here, we demonstrate how screening specifically for anti-
C. difficile lactobacilli identified a strain from the human
GIT with the ability to reduce C. difficile shedding in a
murine model of CDI.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Lactobacillus strains were maintained at −80◦C in 40%
(v/v) glycerol and routinely cultured anaerobically at 37◦C
on MRS agar (Difco, Becton Dickinson, Franklin Lakes,
NJ, United States) for 48 h or overnight in MRS broth.
C. difficile strains EM304 (ribotype 027) and VPI 10463
(see Supplementary Table 1 for details) were maintained at
−80◦C on micro-bank beads (Pro-Lab Diagnostics, Merseyside,
United Kingdom) and cultured on Fastidious Anaerobic
Agar (Lab M, Heywood, Lancashire, United Kingdom)
supplemented with 7% defibrinated horse blood (Cruinn
Diagnostics, Dublin, Ireland) at 37◦C for 3 days. Fresh cultures
were grown overnight at 37◦C in RCM (Merck, Darmstadt,
Germany), pre-boiled and cooled under anaerobic conditions.
The lactobacilli and clostridia were grown in an anaerobic
chamber (Don Whitley, West Yorkshire, United Kingdom)
under an anoxic atmosphere (10% CO2, 10% H2, 80% N2), unless
otherwise stated.
Screening of Lactobacillus Strains for
Anti-bacterial Activity Against
Clostridium difficile
Agar Diffusion Assay
One thousand five hundred Lactobacillus isolates of food,
human and animal origin were assessed for anti-bacterial
activity against C. difficile EM304 using agar diffusion assays.
Lactobacillus strains were grown overnight on MRS agar at 37◦C
anaerobically. C. difficile cells were grown to mid log phase in
RCM and harvested at an optical density (OD600 nm) of 0.8 and
washed twice in preconditioned (pre-boiled and cooled under
anaerobic conditions) MRD (Oxoid Ltd, Basingstoke, England)
and re-suspended in MRD before use. One hundred microliters
of the washed C. difficile cells were mixed with 5 ml BHI agar
(0.7% agar, BHI, Oxoid) and poured onto BHI agar. Lactobacillus
colonies were stabbed from the MRS agar into the C. difficile lawn
with an inoculating needle. Plates were incubated anaerobically
for 24 h and assessed for zones of inhibition.
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In addition L. gasseri APC 678 was assessed for bacteriocin
activity against a range of target organisms, as previously
described (Rea et al., 2010). The full list of target strains,
together with their growth conditions are outlined in
Supplementary Table 2.
Co-culture Broth
Sixty Lactobacillus strains (Table 1) of human and animal origin
were selected for screening using a co-culture method, with
C. difficile EM304 (ribotype 027) (Rea et al., 2012) as the target
strain. A MGM was developed to reflect the limited availability of
simple sugars in the human gut and was buffered to prevent pH
drop during incubation to enable co-culturing of Lactobacillus
and Clostridium strains. The growth medium composition (per
liter) was: meat extract, 2 g; peptone, 2 g; yeast extract, 1 g; NaCl,
5 g; sodium acetate, 0.5 g; L-cysteine hydrochloride, 0.5 g; glucose,
0.1 g; NaH2PO4.H20, 3.7 g; Na2HPO4.7H2O, 6.2 g; pH 6.8 (±0.2).
Following overnight growth, 1 ml of C. difficile EM304 and
each Lactobacillus strain were centrifuged at 14,000 × g. Pelleted
cells were washed once in PBS under anaerobic conditions and
re-suspended in fresh PBS. The MGM was inoculated with a test
strain of Lactobacillus and C. difficile EM304 at ∼106 CFU ml−1.
The cultures were then incubated at 37◦C for 24 h. Survival of
C. difficile was determined by plating onto Brazier’s CCEY (Lab
M) and Lactobacillus counts were determined by plating onto
MRS agar (Difco). Agar plates were incubated anaerobically at
37◦C for 2–3 days and the anti-bacterial activity of the lactobacilli
TABLE 1 | Lactobacilli screened for anti-Clostridium difficile activity.
Lactobacillus spp. No. of strains
tested
Source
L. gasseri 7 Human intestine (2), human
feces (5)
L. salivarius 6 Pig intestine (2), infant feces
(3), human feces (1)
L. plantarum 5 Bovine teat rinse, cow
feces, silage, hand wash,
milking yard water
L. brevis 4 Human feces (2), cow feces
(1), silage (1)
L. casei/paracasei 4 Human feces
L. paracasei 4 Human intestine (2), human
feces (1), yoghurt (1)
L. rhamnosus 4 Human intestine (1), human
feces (3)
L. mucosae 3 Cow feces
L. acidophilus 2 Human feces
L. casei 2 Fermented milk
L. johnsonii 2 Pig intestine, commercial
isolate
L. parabuchneri/kefiri 2 Milk, cow feces
L. reuteri 2 Pig intestine, infant feces
L. rhamnosus/casei 2 Human feces
L. ruminis 2 Human feces
L. murinus 1 Pig cecum
Lactobacillus spp. 8 Human feces
was determined as a reduction in C. difficile counts compared to
the control in the absence of Lactobacillus. Clostridium difficile
VPI 10463, used in the murine model, was also assessed in
co-culture with the three lactobacilli used in the study (L. gasseri
APC 678, L. rhamnosus DPC 6111 and L. gasseri ATCC 33323).
Survival of Lactobacilli During in vitro
Gastrointestinal Transit
The ability of the bacterial strains to survive in a simulated gastric
environment was assessed. Briefly, MRS broth was inoculated
at 1% with the Lactobacillus strains and incubated anaerobically
at 37◦C for 16 h. One milliliter of cells was centrifuged at
14,000× g, washed in PBS and re-centrifuged. The cells were then
re-suspended in PBS or 10% RSM. A suspension of 108 CFU ml−1
Lactobacillus was suspended in artificial gastric juice with the
following composition (per liter): NaCl, 125 mmol; KCl, 7 mmol;
NaHCO3, 45 mmol and pepsin, 3 g. The final pH was adjusted
with HCl to pH 2 or pH 3 or with NaOH to pH 7. The bacterial
suspensions were incubated at 37◦C with agitation (200 rpm).
Viable cells were enumerated at 0, 90 and 180 min.
Following 180 min suspension in simulated gastric juice, the
cells were suspended in simulated intestinal fluid, which was
prepared with 0.10% (w/v) pancreatin (Sigma Aldrich, Ireland)
and 0.15% oxgall bile salts (Difco) in water, adjusted to pH
8.0 with NaOH for a further 180 min. The suspensions were
incubated at 37◦C and samples taken to assess viability on MRS
agar at 90 and 180 min. Plates were incubated at 37◦C for 48 h.
Survival was expressed as log reduction from 0 h.
In vivo Assessment of Lactobacillus
Strains in C. difficile Murine Model
Ethics Statement
All procedures involving animals were approved by the
University College Cork Animal Experimentation Ethics
Committee (#2011/17) and by the HPRA. Animals were
sourced from Harlan Laboratories UK, Bicester, Oxfordshire,
United Kingdom. At the conclusion of the experiment animals
were euthanized by cervical dislocation.
Mouse Model
For the C. difficile model, 40 female C57BL/6 (7 weeks old) mice
were obtained from Harlan Laboratories UK. All mice used in
the experiment were housed in groups of five animals per cage
under the same conditions. Food, water, bedding and cages were
autoclaved before use.
Antibiotic Administration
All mice were made susceptible to CDI by altering the
gut microbiota using a previously described protocol (Chen
et al., 2008). Briefly, an antibiotic mixture comprising of
kanamycin (0.4 mg mL−1), gentamicin (0.035 mg mL−1),
colistin (850 U mL−1), metronidazole (0.215 mg L−1) and
vancomycin (0.045 mg mL−1) was prepared in water (all
antibiotics were purchased from Sigma). This corresponded to
an approximate daily dose for each antibiotic of: kanamycin,
40 mg kg−1; gentamicin, 3.5 mg kg−1; colistin, 4.2 mg kg−1;
metronidazole, 21.5 mg kg−1 and vancomycin, 4.5 mg kg−1.
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The concentrations of antibiotics in the water were calculated
based on the average weight of the animals and expected
daily water consumption of the mice. All mice received the
antibiotic cocktail in water for 3 days, followed by 2 days
of water without antibiotics. All mice received a single dose
of clindamycin 10 mg kg−1 intraperitoneally 1 day before
C. difficile challenge.
Preparation of Bacterial Cultures
Adhering to strict anaerobic conditions, C. difficile VPI 10463
was grown overnight in RCM. Bacterial cells were collected
by centrifugation at 4,050 × g for 5 min, washed once in
preconditioned PBS and re-suspended in PBS to achieve a
preparation of 5 × 105 CFU per mouse. Lactobacillus strains
for each group; L. gasseri APC 678, L. rhamnosus DPC 6111
or L. gasseri ATCC 33323 (see Supplementary Table 1 for
details) were prepared by growing the strains overnight in
MRS broth under anaerobic conditions. Cells were collected
by centrifugation at 4,050 × g for 5 min, washed once in
preconditioned saline solution and re-suspended in 10% (w/v)
RSM to achieve 1 × 109 CFU ml−1. The control group
was fed 10% RSM only. At the start of the experiment all
mice (10/group) received an individual inoculum of C. difficile
(5 × 105 CFU/mouse). Five hours later, 100 µl of the
appropriate probiotic (equivalent to 1 × 108 CFU) or RSM
(control group) was administered by oral gavage, and then
daily for 7 days.
Sample Collection and C. difficile Counts
Prior to commencement of the trial and before antibiotic
treatment, fecal samples were collected from all animals and
plated on CCEY agar to confirm that the mice were C. difficile-
free. Subsequently, fecal pellets were collected at 24 h, 4, and
7 days post-infection with C. difficile and stored anaerobically
before being assessed for viable C. difficile (CFU g−1 feces).
At the end of the trial the mice were sacrificed and total
numbers of C. difficile per colon were counted (CFU colon−1).
C. difficile survival was determined by culturing anaerobically at
37◦C on CCEY agar for 48 h. The putative C. difficile colonies
were confirmed using a C. difficile test kit (Oxoid). Following
euthanasia, cecal contents were collected for compositional
sequencing from each individual mouse, snap frozen and stored
at−80◦C until required.
Microbial DNA Extraction, 16S rRNA
Amplification and Illumina MiSeq
Sequencing
Total metagenomic DNA was extracted for each mouse
cecum (sacrificed 7 days post-infection with C. difficile),
following thawing at 4◦C, with the QIAamp DNA Stool
Mini Kit (Qiagen, Hilden, Germany) with an additional bead
beating step (Murphy et al., 2010). DNA was quantified
using the Nanodrop 1000 spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, United States). Initially
the template DNA was amplified using primers specific
to the V3-V4 region of the 16S rRNA gene which also
allowed for the Illumina overhang adaptor, where the forward
(5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTA
CGGGNGGCWGCAG) and reverse primers (5′GTCTCGTGGG
CTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATC
TAATCC) were used. Each PCR reaction contained 2.5 µl DNA
template (5 ng), 5 µl forward primer (1 µM), 5 µl reverse primer
(1 µM) (Sigma) and 12.5 µl Kapa HiFi Hotstart Readymix
(2X) (Anachem). The template DNA was amplified under the
following PCR conditions: 95◦C for 3 min (initialization); 95◦C
for 30 s (denaturation), 55◦C for 30 s (annealing), and 72◦C for
30 s (elongation) (for a total of 25 cycles); followed by a final
elongation step at 72◦C for 5 min. PCR products were visualized
using gel electrophoresis (1X TAE buffer, 1.5% agarose gel,
100 V). Successful amplicons were cleaned using the AMPure
XP purification system (Labplan, Kildare, Ireland). A second
PCR reaction was completed using the previously amplified and
purified DNA as the template. Two indexing primers (Nextera
XT indexing primers, Illumina, Sweden) were used per sample
to allow all samples to be pooled, sequenced on one flow cell
and subsequently identified bioinformatically. Each reaction
contained 25 µl Kapa HiFi HotStart ReadyMix (2X), 5 µl
template DNA, 5 µl index primer 1 (N7XX), 5 µl index primer
2 (S5XX) and 10 µl PCR grade water. PCR conditions were the
same as previously described with the samples undergoing 8
cycles instead of 25 cycles. Samples were quantified using the
Qubit 2.0 fluorometer (Invitrogen) in conjunction with the broad
range DNA quantification assay kit (Thermo Fisher Scientific).
All samples were pooled to an eqimolar concentration. The
quality of the pool was determined by running on the Agilent
Bioanalyser prior to sequencing. The sample pool was then
denatured with 0.2 M NaOH, diluted to 4 pM and combined
with 10% (v/v) denatured 4 pM PhiX. Samples were sequenced
on the Illumina MiSeq (Teagasc Sequencing Centre, Moorepark,
Fermoy, Co. Cork, Ireland) using a 2300 cycle V3 kit, following
protocols outlined by Illumina.
Bioinformatic Analysis
Raw Illumina 300 base pair paired-end sequence reads were
merged using Flash (Magoc and Salzberg, 2011) and quality
checked using the split libraries script from the QIIME package
(Caporaso et al., 2010). Reads were then clustered into OTUs and
chimeras removed with the 64-bit version of USEARCH (Edgar,
2010). Subsequently OTUs were aligned and a phylogenetic
tree generated within QIIME. Taxonomical assignments were
reached using the SILVA 16S specific database (version 111)
(Quast et al., 2013). Alpha and beta diversity analysis was
also implemented within QIIME. PCoA plots were visualized
using R (version 3.2.2).
Statistical Analysis
Non-parametric statistical analyses (Mann Whitney) were
applied on MiniTab (Version 15) and SPSS (PASW Statistics
version 18) statistical packages, to assess whether differences
in C. difficile shedding, microbiota composition and diversity
between the control and probiotic-fed groups were significant.
Statistical significance was accepted at p < 0.05, adjusted for ties,
where the null hypothesis was rejected.
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Accession Number(s)
Sequence data have been deposited to the ENA under project
accession number PRJEB30242.
RESULTS
Screening for Lactobacilli With
Anti-bacterial Activity Against
Clostridium difficile
Initial screening of hundreds of Lactobacillus isolates for the
production of antibacterial compounds against C. difficile using
an antagonistic agar assay failed to reveal zones of inhibition.
Therefore, a low nutrient medium (MGM) was developed
which more closely represented the low concentration of simple
carbohydrates in the human colon, enabling both Lactobacillus
and C. difficile strains to survive in co-culture over a 24 h
period. Due to the buffering capacity of the medium, the pH
was maintained at near neutral (∼pH 6.5) following incubation
for 24 h, eliminating concerns relating to the reduction of
C. difficile merely as a result of acid production. Since most of
the lactobacilli assessed in the antagonistic agar assay were of
dairy origin, Lactobacillus strains (n = 60) of human, animal, feed
and environmental origin were then selected and screened for
inhibitory activity against C. difficile (Table 1). The co-culture
assay showed that 4 of the 60 lactobacilli tested (L. gasseri
APC 678, L. paracasei APC 1483, L. rhamnosus DPC 6111 and
L. gasseri DPC 6112) had the ability to reduce the survival
of C. difficile EM304 in vitro (Figure 1A). The co-culture of
C. difficile VPI 10463 with each of the three lactobacilli screened
in the mouse study (L. gasseri APC 678, L. rhamnosus DPC 6111
and L. gasseri ATCC 33323) also negatively impacted C. difficile
survival (Figure 1B).
Simulated Gastrointestinal Fluid
Demonstrates Tolerance of Lactobacilli
to Digestion
Among the important probiotic traits required for Lactobacillus
strains intended for use in the GIT is the ability to survive the
acidic conditions of the stomach and the presence of bile in
the upper small intestine. Here, we demonstrate the survival of
L. gasseri APC 678 and L. rhamnosus DPC 6111 in a simulated
GIT environment (Table 2). Both strains, when suspended in PBS
before being added to simulated gastric juice at pH 3 were found
to be stable. However, L. gasseri APC 678 was the more stable of
the two at pH 2, showing a 1.5 log reduction in total viable counts
compared to 3.5 log reduction for L. rhamnosus DPC 6111. Viable
counts indicated that neither strain survived the subsequent 3 h
incubation in simulated ileal juice. However, if the strains were
suspended in 10% RSM prior to treatment with gastric/ileal juice,
their survival was markedly improved both in simulated gastric
juice at both pH 2 and 3 and also after a further 3 h incubation
in ileal juice (Table 2). In 10% RSM L. rhamnosus DPC 6111 was
more sensitive to the overall conditions of the stomach and ileum
than L. gasseri APC 678, showing a 4.4 log reduction at the end
FIGURE 1 | Effect of probiotic lactobacilli on the survival of Clostridium difficile
in co-culture. Black bars () show the cell numbers of C. difficile at 0 and 24 h
in the absence of Lactobacillus strains. Bars with dashed lines ( ) show the
cell numbers of (A) C. difficile EM304 following 24 h co-culture with L. gasseri
APC 678, L. paracasei APC 1483, L. rhamnosus DPC 6111, L. gasseri DPC
6112 or L. gasseri ATCC 33323 and (B) C. difficile VPI 10463 following 24 h
co-culture with L. gasseri APC 678, L. rhamnosus DPC 6111 or L. gasseri
ATCC 33323. The horizontal dashed line (---) indicates the final count of
C. difficile at 24 h in the absence of the Lactobacillus strains. The average and
standard error of the mean (SEM) of three independent repetitions
are represented.
of the incubation period compared with a reduction of 2.8 log for
L. gasseri APC 678.
Lactobacillus Strains Reduce C. difficile
Shedding in a Mouse Model
The ability of L. gasseri APC 678 and L. rhamnosus DPC
6111 to reduce C. difficile shedding in a murine model was
investigated. In addition, the well characterized strain L. gasseri
ATCC 33323 (Azcarate-Peril et al., 2008), was selected as a
control for the animal study. Levels of C. difficile shedding
in the feces, total viable C. difficile in the mouse colon and
changes in the microbiota composition of the mouse cecum were
assessed. Mice were infected with ∼5 × 105 CFU of C. difficile
and at day 1 the mean C. difficile counts were ∼107 CFU g−1
feces in all groups, which compares well with C. difficile counts
in murine studies where the animals received clindamycin or
metronidazole prior to infection with C. difficile (Schubert et al.,
2015). There was no significant reduction in the median counts
of C. difficile shed in the feces between the control and the
Lactobacillus-fed mice after 24 h (Figure 2A). However, after
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TABLE 2 | Survival of lactobacilli during simulated gastrointestinal tract transit.
Log reduction (CFU ml−1) after 3 h in simulated
gastric juice
Log reduction (CFU ml−1) after 3 h in simulated
ileal juice∗
Suspension medium pH L. gasseri APC 678 L. rhamnosus DPC 6111 L. gasseri APC 678 L. rhamnosus DPC 6111
PBS 7.0 0.16 0.21 0.52 0.43
3.0 1.96 1.01 2.19 1.78
2.0 1.52 3.53 8.00 8.00
RSM 7.0 0.84 0.49 0.52 0.13
3.0 1.92 0.91 1.89 2.47
2.0 1.91 1.49 2.82 4.39
The effect of initial suspension medium (PBS or RSM) on the subsequent survival of L. gasseri APC 678 and L. rhamnosus DPC 6111 in simulated gastric juice, followed
by simulated ileal juice. ∗Cells were transferred to simulated ileal juice following 3 h incubation in gastric juice and incubated for an additional 3 h.
FIGURE 2 | Clostridium difficile detected during fecal shedding. C. difficile detected in mouse feces (CFU g−1 feces) following (A) 24 h, (B) 4 days, and (C) 7 days
administration of the test strains (or control); and (D) C. difficile levels in mouse colon (CFU colon−1) following 7 days administration of test strains (or control).
Control: 10% RSM only; APC 678: L. gasseri APC 678; DPC 6111: L. rhamnosus DPC 6111 and ATCC 33323: L. gasseri ATCC 33323. Horizontal bar (__)
represents the median.
4 and 7 days, the presence of L. gasseri APC 678 significantly
reduced C. difficile fecal shedding [11-fold (p = 0.022) and 8-
fold (p = 0.017), respectively; fold reduction was calculated with
median data] compared to the control mice, while there was
no significant reduction in C. difficile in the feces of those mice
receiving either L. rhamnosus DPC 6111 or L. gasseri ATCC
33323 compared to the control mice (Figures 2B,C). It was also
noted that, by day 7, both L. gasseri APC 678 and L. gasseri
ATCC 33323 significantly reduced the numbers of C. difficile
that had adhered to the colon (p = 0.003 and p = 0.014,
respectively; Figure 2D).
Following total metagenomic DNA extraction of the cecal
contents, V3-V4 16S rRNA gene amplicons were generated and
sequenced using the Illumina MiSeq. Diversity, richness and
coverage estimations were calculated for each data set (Table 3),
all of which indicated good sample richness throughout and
the presence of a diverse microbiota. Interestingly, the Simpson
and Shannon diversity metrics were significantly higher in the
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TABLE 3 | Alpha diversity indices for sequencing coverage and microbiota diversity from cecum samples at Day 7 from control and test mice.
Alpha diversity index Control L. gasseri APC 678 L. rhamnosus DPC 6111 L. gasseri ATCC 33323
Chao1 richness estimate 210 ± 79 272 ± 40a 194 ± 38 168 ± 45
Simpson diversity index 0.92 ± 0.03 0.94 ± 0.05∗,a 0.92 ± 0.04 0.89 ± 0.06
Shannon diversity index 4.77 ± 0.70 5.45 ± 0.72∗,a 4.69 ± 0.52 4.41 ± 0.75
PD whole tree 11.69 ± 3.59 14.06 ± 1.71a 11.06 ± 1.63 9.73 ± 1.98
Number of observed species 197 ± 83 259 ± 39a 182 ± 37 153 ± 47
Average and standard deviation of results for 10 mice per treatment are represented. ∗Significantly different compared to the control; asignificantly different compared
to L. rhamnosus DPC 6111 and L. gasseri ATCC 33323; non-parametric Mann–Whitney test was used to estimate the relationship between the groups; statistical
significance was accepted at p < 0.05.
L. gasseri APC 678-fed mice compared to the control mice,
and all alpha diversity indices tested were significantly increased
in the mice fed L. gasseri APC 678 when compared to the
those fed L. gasseri ATCC 33323 or L. rhamnosus DPC 6111,
indicating that L. gasseri APC 678 had a greater positive impact
on diversity than the other lactobacilli tested. Beta-diversity
was estimated using distance matrices built from unweighted
Unifrac distances and subsequently PCoA was performed on
the distance matrices (Figure 3). Every effort was made to
standardize the mice prior to (gender, source, age, antibiotic
administration) and during the treatment and despite possible
cage effect in the control, the groups clustered on the basis of the
strain administered.
Sequence analysis revealed that the microbiota comprised
of 7 main phyla (Table 4, Supplementary Figure 1, and
Supplementary Table 3), with Firmicutes and Bacteroidetes
dominating, and relative abundance corresponding to 28–55%
and 43–71%, respectively. Unlike the group fed L. gasseri APC
678, where no significant change in the abundance of Firmicutes
or Bacteroidetes relative to controls was observed, the groups
fed L. rhamnosus DPC 6111 or L. gasseri ATCC 33323 showed
a significant decrease in the relative abundance of Firmicutes
(p = 0.002 and 0.019, respectively) and a significant increase in
Bacteroidetes (p = 0.002 and 0.023, respectively) relative to the
control. The relative abundance of the phylum Proteobacteria
significantly decreased in the mice fed APC 678 or DPC 6111
relative to the control mice or the animals fed ATCC 33323,
which showed an increase in Proteobacteria relative to the
control. This pattern was mirrored in the significant reduction
of the relative abundance of the genera Escherichia/Shigella
in the groups fed L. gasseri APC 678 or L. rhamnosus DPC
6111. However, the decrease in the relative abundance of
Escherichia/Shigella in the L. gasseri ATCC 33233-fed group
was not significant. A diverse range of microbial families
FIGURE 3 | Principal coordinates analysis (PCoA) of the mouse cecal sequencing data at day 7, based on unweighted UniFrac distances, generated with phyloseq
in R (version 3.2.2). The control and test groups are represented by color; control (red), L. gasseri APC 678 (green), L. rhamnosus DPC 6111 (blue) and L. gasseri
ATCC 33323 (purple) and ggplot2 in R was used to compute the 95% confidence interval for the ellipses.
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(Supplementary Figure 2 and Supplementary Table 4) and
genera (Supplementary Figure 3 and Supplementary Table 5)
were also detected across the four feeding groups. A number
of statistical differences were found at family and genus OTU
levels in the Lactobacillus-fed groups compared to the control
(Table 4). The relative abundance of Peptostreptococcaceae was
significantly reduced in all Lactobacillus-fed groups. This family
encompasses C. difficile. The relative abundance of the genus
Alistipes significantly increased in all Lactobacillus-fed groups
relative to the control. The relative abundance of Rikenellaceae
RC9 gut group also significantly increased in the L. gasseri
APC 678 and L. rhamnosus DPC 6111 groups compared to the
control, with the largest increase associated with the L. gasseri
APC 678-fed group. The relative abundance of Roseburia, known
to be associated with SCFA production (Rios-Covian et al.,
2016), significantly increased in the L. gasseri APC 678-fed
group only. In addition, the relative abundance of Oscillibacter
significantly increased in the groups fed either L. gasseri APC
678 or L. rhamnosus DPC 6111 but not in the L. gasseri ATCC
33323-fed group (Table 4).
DISCUSSION
The increasing frequency of CDI in hospitals, facilities for
the elderly and more recently community settings (Chitnis
et al., 2013), combined with the resulting health and economic
burdens, warrants the search for alternative treatments for
CDI. The use of microbial therapy as a preventive measure to
mitigate the increasing prevalence of CDI is one such avenue
under investigation. Surveys of the literature have shown that
for pediatric use, Lactobacillus strains significantly prevented
antibiotic-associated diarrhea and CDI (Goldenberg et al.,
2013). However, while there was some evidence that microbial
therapy was effective in preventing primary CDI in adults,
there was insufficient evidence to confirm the efficacy of these
strains to prevent recurrent CDI (Evans and Johnson, 2015;
Goldstein et al., 2015).
The concept of strain-specific benefits is not new and has
already been shown to be true of live therapeutics for other
applications (Wall et al., 2012). In this context, our study pre-
screened a range of Lactobacillus species for their ability to inhibit
C. difficile with a view to identifying potential strains to target
CDI in humans. To that end, we developed a medium which
allowed the survival of both Lactobacillus and C. difficile strains in
co-culture, without the decrease in pH normally associated with
the growth of lactobacilli in other media, such as MRS or RCM.
We identified 4 strains from 60 Lactobacillus strains screened (2
L. gasseri strains, 1 L. rhamnosus strain, and 1 L. paracasei strain),
all of human origin, which negatively impacted the growth of
C. difficile in vitro. Among the strains screened was L. gasseri
ATCC 33323, which has a number of traits encoded on its genome
which are important for its survival and retention in the GIT
(Azcarate-Peril et al., 2008). Interestingly, while seven strains
of L. gasseri were screened in vitro only two L. gasseri strains
inhibited C. difficile, lending credence to the theory that not all
TABLE 4 | Relative abundance (%) at bacterial phylum, family and genus level in
the cecum at Day 7 of the control and test mice (Lactobacillus gasseri APC 678,
Lactobacillus rhamnosus DPC 6111 and Lactobacillus gasseri ATCC 33323).
Group Control APC 678 DPC 6111 ATCC 33323
relative abundance (%)
Phylum:
Firmicutes 54.51 37.22 28.44∗ 31.29∗
Bacteroidetes 43.17 62.24 70.62∗ 66.25∗
Proteobacteria 0.47 0.19∗ 0.09∗ 1.29
Actinobacteria 0.26 0.18 0.19 0.13∗
Family:
Lachnospiraceae 40.35 27.46 20.14∗ 23.60∗
S24-7 24.10 31.18 40.72∗ 23.21
Bacteroidaceae 9.29 21.60 18.61 28.21∗
Uncultured Clostridiales 2.01 0.64 0.21∗ 0.58∗
Rikenellaceae 1.86 7.31∗ 6.52∗ 8.11∗
Erysipelotrichaceae 1.80 0.62∗ 0.83∗ 0.95∗
Peptostreptococcaceae 0.60 0.08∗ 0.02∗ 0.05∗
Alcaligenaceae 0.29 0.09∗ 0.069∗ 1.24
Enterobacteriaceae 0.18 0.01∗ 0.02∗ 0.06
Bifidobacteriaceae 0.13 0.04∗ 0.02∗ 0.07∗
Enterococcaceae 0.03 0.02 0.01∗ 0.01
Peptococcaceae 0.00 0.04∗ 0.02 0.07
Prevotellaceae 0.00 0.53 0.56∗ 0.00
Xanthomonadaceae 0.00 0.06∗ 0.00 0.00
Genus:
Uncultured
Lachnospiraceae
29.99 20.93 14.78∗ 18.00∗
Uncultured S24-7 24.10 31.18 40.72∗ 23.21
Bacteroides 9.29 21.60 18.61 28.21∗
Ruminococcaceae
Incertae Sedis
5.36 2.19∗ 1.44∗ 2.01∗
Uncultured Clostridiales 2.01 0.64 0.21∗ 0.58∗
Alistipes 1.41 3.40∗ 4.95∗ 6.03∗
Uncultured
Ruminococcaceae
1.08 2.03∗ 0.77 1.31
Peptostreptococcaceae
Incertae Sedis
0.60 0.08∗ 0.02∗ 0.05∗
Anaerotruncus 0.60 1.09 1.85∗ 0.76
Rikenellaceae RC9 gut
group
0.45 3.90∗ 1.57∗ 2.08
Oscillibacter 0.36 1.15∗ 1.81∗ 0.79
Parasutterella 0.29 0.09∗ 0.07∗ 1.24
Flavonifractor 0.25 0.01∗ 0.01∗ 0.09
Roseburia 0.21 0.90∗ 0.21 0.29
Escherichia-Shigella 0.18 0.01∗ 0.02∗ 0.06
uncultured
Erysipelotrichaceae
0.14 0.04∗ 0.05∗ 0.04∗
Bifidobacterium 0.13 0.04∗ 0.02∗ 0.07∗
Enterococcus 0.03 0.02 0.007∗ 0.01
uncultured
Peptococcaceae
0.00 0.03∗ 0.01 0.07
Prevotella 0.00 0.53 0.56∗ 0.00
Hydrogenoanaerobacterium 0.00 0.004∗ 0.00 0.00
Stenotrophomonas 0.00 0.06∗ 0.00 0.00
Only phyla, families and genera with significant differences compared to the control
mice are represented. ∗Significantly different compared to the control; significance
was determined by p < 0.05.
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strains of the same species have the same effect (Arnold et al.,
2018; Liu et al., 2018).
Two lead candidates from the in vitro work, namely L. gasseri
APC 678 and L. rhamnosus DPC 6111, were selected for in vivo
analysis. These strains have the added advantage of surviving in
higher numbers during simulated gastric transit, at low pH and
in the presence of bile and the digestive enzymes encountered
in the stomach and upper GIT. The increased survival rate in
these environments in the presence of milk is a further bonus
as fermented milk products such as yogurts and cheese are
often used as vehicles for oral delivery of live bacteria (Gardiner
et al., 1998; Hickson et al., 2007). The health impacts of these
Lactobacillus species have been previously investigated (Bravo
et al., 2011; Kadooka et al., 2013; Kechagia et al., 2013; Kobatake
et al., 2017; Wang et al., 2017).
As a first step to determining the efficacy of these strains
with respect to decreasing CDI in vivo, the strains (L. gasseri
APC 678, L. rhamnosus DPC 6111 and the aforementioned well-
characterized L. gasseri ATCC 33323) were tested for their ability
to reduce fecal shedding of C. difficile in a murine model of
CDI over 7 days. During this period, C. difficile VPI 10463 did
not result in the manifestation of obvious signs of disease in the
mice, and as such was regarded for this purpose as a colonization
model of CDI. Clostridium difficile levels were monitored in the
feces by culturing at days 1, 4 and 7 and in the mouse colon
by culturing at Day 7. Sequence analysis was carried out on
the mouse cecal contents at Day 7. The ability to reduce fecal
shedding of C. difficile was significant, when compared to the
control group fed RSM, in those animals fed L. gasseri APC 678
4 days post-infection. This reduction was maintained for up to
7 days, at which time the animals were euthanized. No significant
effect was seen in terms of fecal shedding of C. difficile in those
mice fed either L. gasseri 33323 or L. rhamnosus DPC 6111. In
the initial in vitro co-culture assays, L. rhamnosus DPC 6111
had an equal inhibitory effect to L. gasseri APC 678. However,
this was not reflected in vivo as the L. gasseri APC 678 out-
performed the L. rhamnosus strain. Interestingly, when the level
of viable C. difficile in the colon was assessed the numbers
were significantly reduced in those mice that were fed either of
the L. gasseri strains, which may be as a result of competitive
exclusion of C. difficile by the L. gasseri strains. The absence
of evidence of bacteriocin activity in vitro would suggest that
inhibition of C. difficile by bacteriocins is not responsible. Other
possible means by which the L. gasseri protect the host against
C. difficile include stimulation of the host’s immune response,
competition for nutrients and protection of the integrity of the
gastrointestinal mucosa.
CDI is normally the result of changes to the gut microbiota
as a result of broad-spectrum antibiotic treatment which results
in a decrease in microbial diversity (Rea et al., 2012). One
desired function of a live therapeutic in a disease state would
be to increase microbial diversity, thereby reducing the ability
of C. difficile to survive and multiply due to competition for
nutrients. Compositional sequencing showed that in the control
and the test mice there was a diverse microbiota despite the
prior administration of antibiotics to make the animals more
susceptible to infection. Also, while every effort was made to
standardize the mice prior to and during the study; the PCoA
plot of the cecal sequencing data for the control mice at Day
7 did suggest a separation based on housing. Despite this the
sequencing data from the groups were seen to be statistically
different based on the strain administered. L. gasseri APC
678 increased diversity for all the indices tested, including the
number of observed species, compared to the other strains
studied. It has been recognized that a decrease in diversity
has been linked to CDI (Rea et al., 2012; Gu et al., 2016).
However, unlike the mice fed L. gasseri APC 678, where no
significant change in the relative abundance of the main phyla
was observed when compared to the control, there was a
significant change in the Firmicutes and Bacteroides levels in
the groups fed either L. rhamnosus DPC 6111 or L. gasseri
ATCC 33323 when compared to the control with a significant
increase in Bacteroidetes. The importance, if any, of this shift is
unclear. However, an increase in the abundance of Proteobacteria
(and the genera Escherichia/Shigella) has been associated with
antibiotic use (Cotter et al., 2012) and the animals fed either
L. gasseri APC 678 or L. rhamnosus DPC 6111 showed a
significant decrease in the relative abundance of Proteobacteria
and Escherichia/Shigella, while the change in the animals fed
L. gasseri ATCC 33323 was not significant, establishing that
strains of the same species exert differing effects in this regard.
A study by Schubert and colleagues observed that when the
gut microbiota in a murine model was altered as a result of
antibiotic administration, populations of Porphyromonadaceae,
Lachnospiraceae, Lactobacillus and Alistipes protected against
C. difficile colonization (Schubert et al., 2015). While our study
showed that Lachnospiraceae were significantly reduced in the
groups fed L. rhamnosus DPC 6111 and L. gasseri ATCC 33323
but not the L. gasseri APC 678-fed group, it was notable that the
relative abundance of Alistipes was significantly increased in all
Lactobacillus-fed animals relative to the control group. In a study
in which the microbiota profile of CDI patients were compared,
the relative abundance of Alistipes significantly decreased in the
CDI patients (n = 25) compared to non-CDI patients (n = 30) not
in receipt of antibiotics (Schubert et al., 2015; Milani et al., 2016).
The increase in the relative abundance of genera involved in the
production of SCFAs, such as Roseburia (in L. gasseri APC 678-
fed group) and Oscillibacter (L. gasseri APC 678 or L. rhamnosus
DPC 6111-fed groups) would suggest that lactobacilli can exert
beneficial effects which are strain rather than species specific.
In the fight against CDI it is likely that live therapeutics,
either as well characterized single/multiple strains as described
here or the more complex, less defined microbiota in FMT
will play a role in addressing the reduction in microbial
diversity in the GIT that results from broad spectrum antibiotic
treatment leading to CDI. The interactions between the gut
microbiome and the host are complex and FMT may therefore
have unintended consequences in a patient after successful FMT
due to alteration of the gut microbiota. FMT in experimental
animals has shown that immunologic, behavioral and metabolic
phenotypes can be transferred from donor to recipient, which
may not always be beneficial to the recipient in the long-
term (Collins et al., 2013; Pamer, 2014; Di Luccia et al., 2015).
Therefore, there are advantages to using well characterized strains
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with QPS status (EFSA, 2007) with proven efficacy against
C. difficile in vivo which translate into positive changes in the gut
microbiota profile.
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